Analysts Predict FHLC Will Hit $78
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Source: NASDAQ.COM
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 48.860
Low
66.00
Averages
76.00
High
86.00
Current: 48.860
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes over-the-counter (OTC) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Breathe Right nasal strips, Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prestige Completes LaCorium Acquisition and Prices $400 Million Senior Notes Offering
- Acquisition Completed: Prestige Consumer Healthcare finalized its acquisition of LaCorium Health on July 1, 2026, for approximately $150 million, which is expected to enhance its competitive position in the Australian market where LaCorium holds the #1 position in lip care, potentially driving long-term revenue growth for Prestige.
- Financial Arrangement: The acquisition was financed through cash on hand and existing credit facilities, with LaCorium generating about $40 million in annual revenue and an expected EBITDA of $12 million post-integration, highlighting the financial potential and synergies of the acquisition.
- Bond Offering: Prestige announced a $400 million senior notes offering at a 6.25% interest rate, expected to close on July 15, 2026, aimed at redeeming its outstanding 5.125% senior notes due January 2028, which will lower future interest expenses and optimize its capital structure.
- Earnings Release: Prestige will issue its first quarter fiscal 2027 earnings report on August 6, 2026, and host a conference call to discuss integration progress and future growth strategies, which is anticipated to further bolster investor confidence.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Historic Acquisition: On June 15, Prestige Consumer Healthcare completed its $1.045 billion acquisition of Breathe Right and other OTC brands, marking the largest acquisition in the company's history and expected to generate approximately $200 million in annual revenue, significantly enhancing its market position.
- Brand Expansion Strategy: Breathe Right will not only become Prestige's largest brand but also serve as a strategic pillar in sleep wellness, athletic performance, and allergy relief, with CEO Ron Lombardi indicating plans to replicate the successful expansion model used with Dramamine to broaden consumer awareness and use cases.
- International Market Positioning: Prestige also announced the acquisition of LaCorium Health, a leading therapeutic skincare brand in Australia, further solidifying its presence in the Australian market and highlighting its potential for expansion in the international OTC sector, where consumer trust and brand recognition are increasingly vital.
- Financial Risk Considerations: While the acquisition presents growth opportunities, Prestige's net leverage reached approximately 4.0x EBITDA at closing, with management projecting a reduction to below 3.0x by fiscal 2028, contingent on effective execution and a stable market environment.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Acquisition Expansion: Prestige Consumer Healthcare's $1.045 billion acquisition of Breathe Right and other OTC brands is expected to add approximately $200 million in annual revenue and $95 million in EBITDA, significantly enhancing its market position in sleep, allergy, and wellness sectors.
- Brand Integration Strategy: CEO Ron Lombardi plans to leverage the successful model of Dramamine by enhancing consumer awareness and broadening use cases for Breathe Right, which is anticipated to further solidify Prestige's leadership in the OTC market.
- Market Opportunities: With the rise of GLP-1 weight-loss medications, Prestige's brands like Dramamine and Fleet are actively marketing to users experiencing side effects, showcasing the flexibility and market adaptability of its asset-light model.
- Financial Challenges: While the acquisition enhances Prestige's brand portfolio, it also raises its net leverage to approximately 4.0x EBITDA, with management projecting a reduction to below 3.0x by fiscal 2028, making successful integration and market performance critical factors.
See More
Prestige Consumer Healthcare to Offer $400M New Senior Notes
- Debt Restructuring Plan: Prestige Brands plans to offer up to $400 million in new senior notes due 2034 in a private offering, aiming to optimize its capital structure and reduce financial costs through this initiative.
- Redeeming Old Debt: The company intends to use the net proceeds from this offering, along with cash on hand, to redeem all $400 million of its 5.125% senior notes due 2028, further alleviating future interest burdens.
- Redemption Notice: Prestige Brands expects to notify investors of its intention to redeem the 2028 notes at a price equal to 100% of the principal amount plus accrued and unpaid interest, ensuring investor rights are protected.
- Market Uncertainty: Despite the favorable valuation, analysts note significant uncertainty surrounding Prestige Consumer Healthcare's future, prompting investors to carefully assess the associated risks.
See More
Prestige Consumer Healthcare Shares Plunge 11% Amid Revenue Declines
- Financial Performance Decline: Prestige Consumer Healthcare reported a 5% year-over-year revenue drop in Q4 2026, and a 6.4% decline from the previous quarter, indicating significant challenges in maintaining market competitiveness.
- Supply Chain Issues: During the earnings call, management disclosed that Clear Eyes faced supply constraints, leading to production delays, with shutdowns extending from an expected week to potentially four weeks, exacerbating investor concerns.
- Investigation Launched: Hagens Berman has initiated an investigation into whether Prestige adequately disclosed the performance of the Pillar5 facility and its impact on Clear Eyes supply chain issues prior to May 14, potentially involving violations of federal securities laws.
- Severe Market Reaction: Following the release of disappointing financial results, Prestige's stock price plummeted over 11%, reflecting investor disappointment in the company's future outlook and concerns regarding management transparency.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, highlighting challenges in cost management that may affect profitability.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following this news, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Prestige Completes LaCorium Acquisition and Prices $400 Million Senior Notes Offering
- Acquisition Completed: Prestige Consumer Healthcare finalized its acquisition of LaCorium Health on July 1, 2026, for approximately $150 million, which is expected to enhance its competitive position in the Australian market where LaCorium holds the #1 position in lip care, potentially driving long-term revenue growth for Prestige.
- Financial Arrangement: The acquisition was financed through cash on hand and existing credit facilities, with LaCorium generating about $40 million in annual revenue and an expected EBITDA of $12 million post-integration, highlighting the financial potential and synergies of the acquisition.
- Bond Offering: Prestige announced a $400 million senior notes offering at a 6.25% interest rate, expected to close on July 15, 2026, aimed at redeeming its outstanding 5.125% senior notes due January 2028, which will lower future interest expenses and optimize its capital structure.
- Earnings Release: Prestige will issue its first quarter fiscal 2027 earnings report on August 6, 2026, and host a conference call to discuss integration progress and future growth strategies, which is anticipated to further bolster investor confidence.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Historic Acquisition: On June 15, Prestige Consumer Healthcare completed its $1.045 billion acquisition of Breathe Right and other OTC brands, marking the largest acquisition in the company's history and expected to generate approximately $200 million in annual revenue, significantly enhancing its market position.
- Brand Expansion Strategy: Breathe Right will not only become Prestige's largest brand but also serve as a strategic pillar in sleep wellness, athletic performance, and allergy relief, with CEO Ron Lombardi indicating plans to replicate the successful expansion model used with Dramamine to broaden consumer awareness and use cases.
- International Market Positioning: Prestige also announced the acquisition of LaCorium Health, a leading therapeutic skincare brand in Australia, further solidifying its presence in the Australian market and highlighting its potential for expansion in the international OTC sector, where consumer trust and brand recognition are increasingly vital.
- Financial Risk Considerations: While the acquisition presents growth opportunities, Prestige's net leverage reached approximately 4.0x EBITDA at closing, with management projecting a reduction to below 3.0x by fiscal 2028, contingent on effective execution and a stable market environment.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Acquisition Expansion: Prestige Consumer Healthcare's $1.045 billion acquisition of Breathe Right and other OTC brands is expected to add approximately $200 million in annual revenue and $95 million in EBITDA, significantly enhancing its market position in sleep, allergy, and wellness sectors.
- Brand Integration Strategy: CEO Ron Lombardi plans to leverage the successful model of Dramamine by enhancing consumer awareness and broadening use cases for Breathe Right, which is anticipated to further solidify Prestige's leadership in the OTC market.
- Market Opportunities: With the rise of GLP-1 weight-loss medications, Prestige's brands like Dramamine and Fleet are actively marketing to users experiencing side effects, showcasing the flexibility and market adaptability of its asset-light model.
- Financial Challenges: While the acquisition enhances Prestige's brand portfolio, it also raises its net leverage to approximately 4.0x EBITDA, with management projecting a reduction to below 3.0x by fiscal 2028, making successful integration and market performance critical factors.
See More
Prestige Consumer Healthcare to Offer $400M New Senior Notes
- Debt Restructuring Plan: Prestige Brands plans to offer up to $400 million in new senior notes due 2034 in a private offering, aiming to optimize its capital structure and reduce financial costs through this initiative.
- Redeeming Old Debt: The company intends to use the net proceeds from this offering, along with cash on hand, to redeem all $400 million of its 5.125% senior notes due 2028, further alleviating future interest burdens.
- Redemption Notice: Prestige Brands expects to notify investors of its intention to redeem the 2028 notes at a price equal to 100% of the principal amount plus accrued and unpaid interest, ensuring investor rights are protected.
- Market Uncertainty: Despite the favorable valuation, analysts note significant uncertainty surrounding Prestige Consumer Healthcare's future, prompting investors to carefully assess the associated risks.
See More
Prestige Consumer Healthcare Shares Plunge 11% Amid Revenue Declines
- Financial Performance Decline: Prestige Consumer Healthcare reported a 5% year-over-year revenue drop in Q4 2026, and a 6.4% decline from the previous quarter, indicating significant challenges in maintaining market competitiveness.
- Supply Chain Issues: During the earnings call, management disclosed that Clear Eyes faced supply constraints, leading to production delays, with shutdowns extending from an expected week to potentially four weeks, exacerbating investor concerns.
- Investigation Launched: Hagens Berman has initiated an investigation into whether Prestige adequately disclosed the performance of the Pillar5 facility and its impact on Clear Eyes supply chain issues prior to May 14, potentially involving violations of federal securities laws.
- Severe Market Reaction: Following the release of disappointing financial results, Prestige's stock price plummeted over 11%, reflecting investor disappointment in the company's future outlook and concerns regarding management transparency.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, highlighting challenges in cost management that may affect profitability.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following this news, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
